Table 4.

Subgroup analysis of elevated CRP (>10 mg/L) and risk of breast cancer–specific mortality in breast cancer survivors in the WHEL study

Stratified multivariable-adjusted model
Stratified models of association by upper quartile of CRPNo. of eventsNHR95% CIPa
Age, y0.92
 <551151,9361.420.81–2.50
 ≥55739832.081.07–4.05
Postmenopausal0.74
 No385950.860.26–2.66
 Yes1502,3241.891.19–3.02
BMI, kg/m20.56
 18.5–24.9701,2491.080.26–4.56
 ≥251191,6971.841.18–2.88
Tumor stage0.32
 I251,1442.510.82–7.64
 II–III1631,7751.550.97–2.47
Tumor ER0.18
 ER positive1202,1711.981.17–3.38
 ER negative667101.330.65–2.72
CVD0.99
 No history of CVD1111,8011.440.93–2.22
 History of CVD396051.170.56–2.43
Arthritis0.64
 No history of arthritis1211,9441.470.94–2.59
 History of arthritis294622.820.99–8.00
Type 2 diabetes0.65
 No history of T2DM1392,2951.460.86–2.50
 History of T2DM111112.270.55–9.44

NOTE: Adjusted for the following variables, including age, time since diagnosis tumor, postmenopausal status, tumor stage, tumor grade, race–ethnicity, BMI, anti-estrogen use, and ER/PR status, unless stratified by specific variable.

  • aTwo-sided P for interaction.